Rubaz 3 mg / 0,02 mg FC tablets
PDF Leaflet Revision Date: 21 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Oral contraceptive; treatment of moderate acne and PMDD.
Dosage (summary)
One tablet daily for 28 days, starting on day 1 of the menstrual cycle.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Enzyme inducers
- HIV protease inhibitors
- Antibiotics
Contraindications
- Hypersensitivity to components
- Thromboembolic disorders
- Severe hepatic disease
- Severe renal impairment
Common side effects
- Nausea
- Headache
- Breast pain
- Mood changes
Counselling Points
- Use barrier contraception if pills are missed
- Regular breast examinations recommended
- Report mood changes or severe side effects
Serious warnings
- Increased risk of thromboembolism
- Monitor for hypertension
- Potential for breast cancer risk
Important Disclaimer
The Rubaz 3 mg / 0,02 mg FC tablets professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
